PMID- 22432792
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20221207
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 28
IP  - 3
DP  - 2013 Mar
TI  - Impact of pretransplant antinuclear antibody and antismooth muscle antibody 
      titers on disease recurrence and graft survival following liver transplantation 
      in autoimmune hepatitis patients.
PG  - 537-42
LID - 10.1111/j.1440-1746.2012.07125.x [doi]
AB  - BACKGROUND AND AIMS: Disease recurrence following transplantation occurs in 
      20-45% of patients with autoimmune hepatitis (AIH). Factors associated with an 
      increased risk of recurrence include human leukocyte antigen (HLA) DR3 and HLA 
      DR4 positivity, inadequate immunosuppression, and severity of inflammation in the 
      native liver. Titers of several autoantibodies can be elevated in patients with 
      AIH, including antinuclear antibody (ANA) and antismooth muscle antibody (SMA); 
      however, it is unclear whether or not the degree of elevation influences the risk 
      of disease recurrence following transplantation. METHODS: We conducted a 
      retrospective study to evaluate the potential impact of pretransplant titers on 
      post-transplant outcomes for patients with AIH. Sixty-three patients with AIH who 
      underwent 72 liver transplants between 1 January 1989 and 1 January 2009 were 
      included, with a median follow up of 10 months. Patients were divided into group 
      A (ANA or SMA >/= 1:160) and group B (titers </= 1:160). RESULTS: There was no 
      significant difference in the recurrence rates or death between patients in 
      groups A and B, respectively. Only race appeared to impact outcomes, with African 
      American patients having a higher incidence of death and recurrent disease 
      post-transplant compared to other ethnicities. CONCLUSIONS:   Based on our 
      findings, pretransplant ANA and SMA levels do not appear to impact recurrence 
      rates or outcomes following liver transplantation for AIH.
CI  - (c) 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Dbouk, Nader
AU  - Dbouk N
AD  - Department of Internal Medicine, Emory University School of Medicine, Atlanta, 
      Georgia 30322, USA. ndbouk@emory.edu
FAU - Parekh, Samir
AU  - Parekh S
LA  - eng
GR  - UL1 RR025008/RR/NCRR NIH HHS/United States
GR  - UL1 RR025008-01/RR/NCRR NIH HHS/United States
GR  - UL1 TR000454/TR/NCATS NIH HHS/United States
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (anti-liver kidney microsome antibody)
SB  - IM
MH  - Adult
MH  - Black or African American
MH  - Antibodies, Antinuclear/blood
MH  - Autoantibodies/*blood
MH  - Biomarkers/blood
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - Follow-Up Studies
MH  - Graft Survival/*immunology
MH  - Hepatitis, Autoimmune/ethnology/immunology/mortality/*surgery
MH  - Humans
MH  - Liver Transplantation/*immunology
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Preoperative Period
MH  - Recurrence
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
PMC - PMC3388173
MID - NIHMS364537
EDAT- 2012/03/22 06:00
MHDA- 2013/08/27 06:00
PMCR- 2014/03/01
CRDT- 2012/03/22 06:00
PHST- 2012/03/22 06:00 [entrez]
PHST- 2012/03/22 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
PHST- 2014/03/01 00:00 [pmc-release]
AID - 10.1111/j.1440-1746.2012.07125.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2013 Mar;28(3):537-42. doi: 
      10.1111/j.1440-1746.2012.07125.x.